These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 7729900)
1. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Cherniak R; Morris LC; Belay T; Spitzer ED; Casadevall A Infect Immun; 1995 May; 63(5):1899-905. PubMed ID: 7729900 [TBL] [Abstract][Full Text] [Related]
2. Structure of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans serotype C as determined by 2D 1H NMR spectroscopy. Bacon BE; Cherniak R Carbohydr Res; 1995 Oct; 276(2):365-86. PubMed ID: 8542606 [TBL] [Abstract][Full Text] [Related]
3. Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay. Belay T; Cherniak R Infect Immun; 1995 May; 63(5):1810-9. PubMed ID: 7537249 [TBL] [Abstract][Full Text] [Related]
4. Structure of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans Cap70 as determined by 2D NMR spectroscopy. Bacon BE; Cherniak R; Kwon-Chung KJ; Jacobson ES Carbohydr Res; 1996 Mar; 283():95-110. PubMed ID: 8901265 [TBL] [Abstract][Full Text] [Related]
5. Structural variability in the glucuronoxylomannan of Cryptococcus neoformans serotype A isolates determined by 13C NMR spectroscopy. Turner SH; Cherniak R; Reiss E; Kwon-Chung KJ Carbohydr Res; 1992 Sep; 233():205-18. PubMed ID: 1446309 [TBL] [Abstract][Full Text] [Related]
7. Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay. Belay T; Cherniak R; Shinoda T Infect Immun; 1993 Jul; 61(7):2879-85. PubMed ID: 7685739 [TBL] [Abstract][Full Text] [Related]
8. Structure of the 13C-enriched O-deacetylated glucuronoxylomannan of Cryptococcus neoformans serotype A determined by NMR spectroscopy. Sheng S; Cherniak R Carbohydr Res; 1997 Jun; 301(1-2):33-40. PubMed ID: 9228737 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen. Percival A; Thorkildson P; Kozel TR Clin Vaccine Immunol; 2011 Aug; 18(8):1292-6. PubMed ID: 21697342 [TBL] [Abstract][Full Text] [Related]
10. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223 [TBL] [Abstract][Full Text] [Related]
12. A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans. Probert M; Zhou X; Goodall M; Johnston SA; Bielska E; Ballou ER; May RC Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670549 [TBL] [Abstract][Full Text] [Related]
13. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody. Zhang H; Zhong Z; Pirofski LA Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446 [TBL] [Abstract][Full Text] [Related]
14. Glucuronoxylomannan of Cryptococcus neoformans serotype B: structural analysis by gas-liquid chromatography-mass spectrometry and 13C-nuclear magnetic resonance spectroscopy. Turner SH; Cherniak R Carbohydr Res; 1991 Apr; 211(1):103-16. PubMed ID: 1773425 [TBL] [Abstract][Full Text] [Related]
15. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens. Pirofski LA Trends Microbiol; 2001 Sep; 9(9):445-51. PubMed ID: 11553457 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures. Oscarson S; Alpe M; Svahnberg P; Nakouzi A; Casadevall A Vaccine; 2005 Jun; 23(30):3961-72. PubMed ID: 15917118 [TBL] [Abstract][Full Text] [Related]
17. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies. Mukherjee J; Kozel TR; Casadevall A J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of Cryptococcus neoformans var. neoformans (Serotype D) and Cryptococcus neoformans var. grubii (Serotype A) isolates in New York City. Steenbergen JN; Casadevall A J Clin Microbiol; 2000 May; 38(5):1974-6. PubMed ID: 10790132 [TBL] [Abstract][Full Text] [Related]
20. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals. Deshaw M; Pirofski LA Clin Exp Immunol; 1995 Mar; 99(3):425-32. PubMed ID: 7882565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]